News

The history of new treatments coming to schizophrenia should serve as a warning...

The movie “Inside Out 2”: good for mental health explorations for individuals of all ages.

Write to us now to be part of our series focused on schizophrenia this month.

An expert offers a critical examination of the "slippery slope" argument.

Let's explore psychological themes in summer movies.

What are your thoughts on the presidential debate?

Here are highlights from the week in Psychiatric Times.

Ideas are a product of their context.

"How free is our will if our fate is decided by our melanin. What is the meaning of Black lives when so many people don’t think we matter?"

H. Steven Moffic, MD, recaps his vacation and the impact it had on his state of mind.

What questions would you ask the presidential debaters?

While ketamine is a not approved for the treatment of depression or chronic pain, clinicians have shown increased interest in using it for these conditions. An FDA workshop is exploring its potential.

June held negative news for psychedelics and an accepted sNDA for brexpiprazole + sertraline for adults with PTSD.

Are you going on vacation this year? Here's why you should.

Experts share the results from the first-in-human phase 1 study of this treatment, plus a preview of its upcoming phase 2 trial.

A look into the experiential learning process involving ketamine.

Not knowing the pathophysiology of a condition does not mean we have no causal explanation of the patient’s suffering and incapacity.

An update on recent advances and learnings from ongoing studies.

Mental health clinicians and legal practitioners can learn more about parental alienation and its treatment here.

Check out these recommendations for facilitating conflict resolution.

How does climate change affect mental health in individuals and communities?

Judith Joseph, MD, MBA, shares her journey of balancing clinical work with social media mental health advocacy.

What is lifestyle psychiatry, and how can it benefit our patients?

Experts present the results of a retrospective analysis of patients who received IV ketamine for TRD over a timeframe of up to 2 years.

Travel: how can it heal you?

An expert discusses this comorbidity, plus the effects of semaglutide and other GLP-1 agonists on this patient population.

The FDA has approved its supplemental New Drug Application for Wakix tablets for the treatment of excessive daytime sleepiness in pediatric patients aged 6 years and older with narcolepsy.

Additionally, 27% of US adults have reported they have a disability across a spectrum of areas.

Do we need a potential classification of social psychoexemplaries?

Here are highlights from the week in Psychiatric Times.